← Leaderboards
Sean M. Murphy
Friends Research Institute, Inc.
$8,373,847
Attributed
$16,784,537
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,055,126 · 8
By mechanism
R01$14,728,055 · 5
P30$3,488,871 · 2
U24$838,200 · 1
Top collaborators
- Paul W Glimcher7 shared
- Cathy J Reback7 shared
- Babak Tofighi7 shared
- Nathalie Hill-Kapturczak3 shared
- Michael G Mcdonell3 shared
- John P Rotrosen3 shared
- Kathryn E Mccollister1 shared
- Bruce R Schackman1 shared
Most similar at Friends Research Institute, Inc.
Same institution · by research overlap
- Jan Gryczynski$15,962,910
Others in their field
Other Emerging Leaders on “Effectiveness”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Leonard Freedman · Leidos Biomedical Research, Inc.$90,203,558
Research focus
EffectivenessResourcesProductivityCostCost EffectivenessPolicy MakerSubstance Use DisorderHealth Care CostsRandomizedQuality-Adjusted Life YearsCaringEconomic EvaluationServicesTreatment As UsualSafety NetOpioidProviderEconomicsPublic HealthHealth Care SectorPoliciesResponseParticipantCommunities
Grant awards (28)
Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation$2,270,589
P30 · FY2025 · DA
SOAR: Smartphones for Opioid Addiction Recovery$970,164
R01 · FY2025 · DA
Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression$917,615
R01 · FY2025 · DA
Optimizing PrEP Implementation and Cost-effectiveness among Individuals with a Substance Use Disorder$901,066
R01 · FY2025 · DA
JCOIN Phase II Economic Research Resource Center$838,200
U24 · FY2025 · DA · contact PI
Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults with AUD$691,670
R01 · FY2025 · AA
SOAR: Smartphones for Opioid Addiction Recovery$140,800
R01 · FY2025 · DA
SOAR: Smartphones for Opioid Addiction Recovery$1,011,393
R01 · FY2024 · DA
Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder$912,089
R01 · FY2024 · DA
Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression$896,441
R01 · FY2024 · DA
Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults with AUD$691,670
R01 · FY2024 · AA
Core 2: Methodology$239,931
P30 · FY2024 · DA · contact PI
SOAR: Smartphones for Opioid Addiction Recovery$158,414
R01 · FY2024 · DA
SOAR: Smartphones for Opioid Addiction Recovery$1,011,246
R01 · FY2023 · DA
Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder$908,730
R01 · FY2023 · DA
Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults with AUD$715,994
R01 · FY2023 · AA
Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression$636,993
R01 · FY2023 · DA
Core 2: Methodology$240,067
P30 · FY2023 · DA · contact PI
SOAR: Smartphones for Opioid Addiction Recovery$1,010,866
R01 · FY2022 · DA
Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder$594,260
R01 · FY2022 · DA
Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use Disorder$383,794
R01 · FY2022 · DA · contact PI
Core 2: Methodology$239,931
P30 · FY2022 · DA · contact PI
SOAR: Smartphones for Opioid Addiction Recovery$989,878
R01 · FY2021 · DA
Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use Disorder$383,833
R01 · FY2021 · DA · contact PI
Core 2: Methodology$240,371
P30 · FY2021 · DA · contact PI
Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use Disorder$384,567
R01 · FY2020 · DA · contact PI
Core 2: Methodology$257,982
P30 · FY2020 · DA · contact PI
Health and Economic Outcomes of Treatment with Extended-Release Naltrexone Among Pre-Release Prisoners with Opioid Use Disorder$416,572
R01 · FY2019 · DA · contact PI